Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Snynf crawled date : 2022 - 09 - 05 save search
Global Treatment Resistant Depression Market to Surpass US$ 1,545.6 Million by 2030 - Coherent Market Insights
Published: 2022-09-05 (Crawled : 19:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
|
| O: 0.6%
H: 0.0%
C: -4.59%
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -2.93%
H: 10.14%
C: 3.79%
ATAI | $1.87 -5.08% -5.07% 0
|
Manufacturing
|
| O: 1.61%
H: 0.45%
C: -4.97%
VTRS | News A | $11.55 1.67% 1.65% 4.4M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: -0.84%
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
|
| O: -0.63%
H: 0.35%
C: -0.57%
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
|
| O: 0.54%
H: 3.26%
C: 1.28%
BHC | $8.56 0.35% 0.47% 1.1M
|
Health Technology
|
| O: 0.47%
H: 1.39%
C: 0.15%
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
|
| O: 0.75%
H: 1.49%
C: 0.21%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: 0.0%
treatment global depression market
Global Osteoarthritis Drugs Market to surpass US$ 16,184.9 million by 2030 - Coherent Market Insights
Published: 2022-09-05 (Crawled : 18:00) - prnewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
| Email alert
Add to watchlist
RDUS | $17.91 1.53% 1.45% 320K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
AVNS | $18.71 -0.27% 0.0% 1
|
Health Technology
| Email alert
Add to watchlist
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
| Email alert
Add to watchlist
osteoarthritis global market
Vitiligo Treatment Market Size Worth US$ 2.42 Billion With CAGR of 6.14% from 2022 to 2030 | Exclusive Report by Growth Plus Reports
Published: 2022-09-05 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 0
|
Health Technology
| Email alert
Add to watchlist
ALPMF | News | $9.5 -2.56% 43.47% 6.8K
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
ALPMY | News | $9.47 -0.21% -1.11% 20K
|
Manufacturing
| Email alert
Add to watchlist
GSK | News | $40.86 -0.92% 0.91% 11K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
ABBV | News | $167.8 -1.03% -0.02% 2.9M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
| Email alert
Add to watchlist
treatment report plus growth market
Late-Breaking Dupixent® (dupilumab) Data at ERS 2022 Show Consistent Efficacy and Safety Profile for Up to Two Years in Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Published: 2022-09-05 (Crawled : 12:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
dupixent children
Outlook on the Hereditary Angioedema Global Market to 2030 - Size, Share, Outlook, and Opportunity Analysis
Published: 2022-09-05 (Crawled : 11:00) - prnewswire.com
CNTG | $0.461 -3.96% -1.05% 20K
|
Commercial Services
| Email alert
Add to watchlist
ADVM | News | $10.19 -7.36% -7.95% 400K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
IONS | $42.45 1.46% 1.45% 730K
|
Health Technology
| Email alert
Add to watchlist
BCRX | News | $4.21 -3.88% -3.79% 12
|
Health Technology
| Email alert
Add to watchlist
ARWR | $23.29 -2.06% -2.13% 810K
|
Health Technology
| Email alert
Add to watchlist
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
| Email alert
Add to watchlist
global market hereditary angioedema
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET™ Platform at ESMO 2022
Published: 2022-09-05 (Crawled : 08:00) - biospace.com/
IPHA | $2.46 3.8% 4.05% 690
|
Health Technology
| Email alert
Add to watchlist
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
IPHYF | $2.65 104.6% 300
|
Health Technology
| Email alert
Add to watchlist
pharma platform phase 2b
Press Release: Evolution of the Board of Directors
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma
Published: 2022-09-05 (Crawled : 06:00) - globenewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
dupixent children
FDA Review: Immusoft, BioCryst, Intellia and More
Published: 2022-09-05 (Crawled : 05:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
fda
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
Published: 2022-09-05 (Crawled : 01:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.71% 8K
|
Health Technology
| Email alert
Add to watchlist
INCY | $51.74 0.17% 0.14% 2
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
obesity chinese trial phase 2
ESMO Presentations of Libtayo® (cemiplimab), Fianlimab and Novel Bispecific Antibodies Showcase Expanding Potential of Regeneron's Oncology Pipeline in Multiple Cancers
Published: 2022-09-04 (Crawled : 00:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.54 -0.09% -0.08% 280K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
| Email alert
Add to watchlist
libtayo potential
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
MTH | $154.69 -2.21% 7.56% 64
|
Consumer Durables
ASXC | $0.243 -2.41% 7.0% 1.1M
|
Manufacturing
IHT P | $1.3712 0.82% 6.48% 0
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.